Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men

Urology

Volumn 61, Issue 5, 2003, Pages 987-992

  Gueye, S M ^a   Zeigler Johnson, C M ^b   Friebel, T ^b   Spangler, E ^b   Jalloh, M ^b   MacBride, S ^b   Malkowicz, S B ^b   Rebbeck, T R ^b  

^a Center for Clinical Epidemiology and Biostatistics   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBSERVATION; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE CANCER; SENEGAL; SYMPTOM; UNITED STATES; WESTERN HEMISPHERE;

EID: 0038640093     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02588-8     Document Type: Article

References (26)

1. Ries LAG, Eisner MP, Kosary CL, et al (Eds): SEER Cancer Statistics Review, 1973-1999. Bethesda, Maryland, National Cancer Institute. http://seer.cancer.gov/csr/1973_1999/, 2002.
2. Landis S.H., Taylor M., Bolden S., et al. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
3. Polednak A.P., Flannery J.T. Black versus white racial differences in clinical stage at diagnosis and treatment of prostate cancer in Connecticut. Cancer. 70:1992;2152-2158.
4. Powell I.J., Heilbrun L.K., Sakr W., et al. The predictive value of race as clinical prognostic factor among patients with clinically localized prostate cancer a multivariate analysis of positive surgical margins . Urology. 49:1997;726-731.
5. Moul J.W., Douglas T.H., McCarthy W.F., et al. Black race in adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 155:1996;1667-1673.
6. Glover F.E. Jr, Coffey D.S., Douglas L.L., et al. The epidemiology of prostate cancer in Jamaica. J Urol. 159:1998;1984-1986.
7. Antopulos I.M., Pompeo A.C.L., El Hayek O.R., et al. Results of prostate cancer screening in non symptomatic men. Braz J Urol. 27:2001;227-234.
8. Silverberg E., Lubera J.A. Cancer statistics - 1989. CA Cancer J Clin. 39:1989;3-20.
9. Ernster V.L., Selvin S., Winkelstein W. Cohort mortality for prostatic cancer among United States non-whites. Science. 200:1978;1165-1166.
10. Platz E., Rimm E.B., Willet W.C., et al. Racial variation in prostate cancer incidence and in hormonal systems markers among male health professionals. J Natl Cancer Inst. 92:2000;2009-2017.
11. Osegbe D.N. Prostate cancer in Nigerians facts and nonfacts . J Urol. 157:1997;1340-1343.
12. Shirley S.E., Escofferey C.T., Sargeant L.A., et al. Clinicopathological features of prostate cancer in Jamaican men. BJU Int. 89:2002;390-395.
13. Ravery V., Javerliat I., Toublanc M., et al. Caracteristiques des cancers prostatiques chez les francais d'origine afro-antillaise. Prog Urol. 10:2000;231-236.
14. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for serum prostate specific antigen in black men. N Engl J Med. 335:1996;304-310.
15. Freedland S.J., Sutter M.E., Naitoh J., et al. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology. 55:2000;387-390.
16. William W.H., Critz F.A., Benton J.B., et al. African American men with prostate cancer treated by simultaneous irradiation. Prostate J. 2:2000;80-87.
17. Moul J.W., Sesterhenn I.A., Connelly R.R., et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 274:1995;1277-1281.
18. Presti J.C., Hovey R., Bhargava V., et al. Prospective evaluation of prostate-specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate ethnic variations . J Urol. 157:1997;907-911.
19. Young C.D., Roach M. Race and prostate cancer what do we know? Prostate J. 2:2000;33-41.
20. Borre M., Nerstrom B., Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer. 80:1997;917-928.
21. Bennet C.L., Ferreira M.R., Davis T.C., et al. Relation between literacy, race and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 16:1998;101-104.
22. Dennis L.K., Lynch C.F., Torner J.C. Epidemiologic association between prostatitis and prostate cancer. Urology. 60:2002;78-83.
23. Perron L., Moore L., Bairati I., et al. PSA screening and prostate cancer mortality. CMAJ. 166:2002;586-591.
24. Fowler J.E., Bigler S.A., Farabaugh P.B. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/ml. Cancer. 94:2002;1661-1667.
25. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific-antigen mass screening in the federal state of Tyrol, Austria. Urology. 58:2001;417-424.
26. D'Amico A., Whittington R., Malkowicz B., et al. Estimating the impact on prostate cancer mortality of incorporating prostate-specific-antigen testing into screening. Urology. 58:2001;406-410.